The class I phosphoinositide 3-kinases α and β control antiphospholipid antibodies-induced platelet activation

Summary

Antiphospholipid syndrome (APS) is an autoimmune disease characterised by the presence of antiphospholipid antibodies (aPL) associated with increased thrombotic risk and pregnancy morbidity. Although aPL are heterogeneous auto-antibodies, the major pathogenic target is the plasma protein β2-glycoprotein 1. The molecular mechanisms of platelet activation by aPL remain poorly understood. Here, we explored the role of the class IA phosphoinositide 3-kinase (PI3K) α and β isoforms in platelet activation by aPL. Compared to control IgG from healthy individuals, the IgG fraction isolated from patients with APS potentiates platelet aggregation induced by low dose of thrombin in vitro and increases platelet adhesion and thrombus growth on a collagen matrix under arterial shear rate through a mechanism involving glycoprotein Ib (GPIb) and Toll Like Receptor 2 (TLR-2). Using isoforms-selective pharmacological PI3K inhibitors and mice with megakaryocyte/platelet lineage-specific inactivation of class IA PI3K isoforms, we demonstrate a critical role of the PI3Kβ and PI3Kα isoforms in platelet activation induced by aPL. Our data show that aPL potentiate platelet activation through GPIbα and TLR-2 via a mechanism involving the class IA PI3Kα and β isoforms, which represent new potential therapeutic targets in the prevention or treatment of thrombotic events in patients with APS.

Keywords

Antiphospholipid antibodies - blood platelets - phosphoinositide 3-kinases - thrombosis

• References

• 1 Galli M, Luciani D, Bertolini G. et al. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-2723.
• 2 de Groot PG, Urbanus RT. The significance of autoantibodies against β2-glycoprotein I. Blood 2012; 120: 266-274.
• 3 Arad A, Proulle V, Furie RA. et al. β1-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011; 117: 3453-3459.
• 4 De Laat B, Derksen RH, van Lummel M. et al. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107: 1916-1924.
• 5 Forastiero R, Martinuzzo M, de Larrañaga G. et al. Anti-β2glycoprotein I antibodies from leprosy patients do not show thrombogenic effects in an in vivo animal model. J Thromb Haemost 2011; 04: 859-861.
• 6 Ioannou Y, Pericleous C, Giles I. et al. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 280-290.
• 7 Bontadi A, Ruffatti A, Falcinelli E. et al. Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thromb Haemost 2013; 109: 901-908.
• 8 Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus 1994; 03: 247-251.
• 9 Ramesh S, Morrell CN, Tarango C. et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest 2011; 121: 120-131.
• 10 Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT. et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 2011; 117: 1408-1414.
• 11 Fischetti F, Durigutto P, Pellis V. et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-2346.
• 12 Satta N, Dunoyer-Geindre S, Reber G. et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007; 109: 1507-1514.
• 13 Allen KL, Fonseca FV, Betapudi V. et al. A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood 2012; 119: 884-893.
• 14 Shi T, Giannakopoulos B, Yan X. et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54: 2558-2567.
• 15 Pennings MT, Derksen RH, van Lummel M. et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2’. J Thromb Haemost 2007; 05: 369-377.
• 16 Lutters BC, Derksen RH, Tekelenburg WL. et al. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2’. J Biol Chem 2003; 278: 33831-33838.
• 17 Proulle V, Furie RA, Merrill-Skoloff G. et al. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood 2014; 124: 611-622.
• 18 Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50: 2911-2919.
• 19 Jankowski M, Vreys I, Wittevrongel C. et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 157-162.
• 20 Urbanus RT, Pennings MT, Derksen RH. et al. Platelet activation by dimeric beta2-glycoprotein I requires signalling via both glycoprotein Ibalpha and apolipoprotein E receptor 2’. J Thromb Haemost 2008; 06: 1405-1412.
• 21 Vanhaesebroeck B, Guillermet-Guibert J, Graupera M. et al. The emerging mechanisms of isoform-specific PI3K signalling. Nature Rev Mol Cell Biol 2010; 11: 329-341.
• 22 Laurent PA, Severin S, Gratacap MP. et al. Class I PI 3-kinases signalling in platelet activation and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1. Adv Biol Regul 2014; 54: 162-174.
• 23 Jackson SP, Yap CL, Anderson KE. Phosphoinositide 3-kinases and the regulation of platelet function. Biochem Soc Trans 2004; 32: 387-392.
• 24 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 04: 295-306.
• 25 Martin V, Guillermet-Guibert J, Chicanne G. et al. Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 2010; 115: 2008-2013.
• 26 Laurent PA, Séverin S, Hechler B. et al. Platelet PI3Kβ and GSK3 regulate thrombus stability at high shear rate. Blood 2015; 125: 881-888.
• 27 Soulet C, Hechler B, Gratacap MP. et al. C. A differential role of the platelet ADP receptors P2Y1 and P2Y12 in Rac activation. J Thromb Haemost 2005; 03: 2296-2306.
• 28 Alard JE, Gaillard F, Daridon C. et al. TLR2 is one of the endothelial receptors for beta 2-glycoprotein I. J Immunol 2010; 185: 1550-1557.
• 29 Poulton K, Rahman A, Giles I. Examining how antiphospholipid antibodies activate intracellular signalling pathways: a systematic review. Semin Arthritis Rheum 2012; 41: 720-736.
• 30 Blair P, Rex S, Vitseva O. et al. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res 2009; 104: 346-354.
• 31 Fälker K, Klarström-Engström K, Bengtsson T. et al. The toll-like receptor 2/1 (TLR2/1) complex initiates human platelet activation via the src/Syk/LAT/PLCγ2 signalling cascade. Cell Signal 2014; 02: 279-286.
• 32 Beaulieu LM, Freedman JE. The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes. Thromb Res 2010; 125: 205-209.
• 33 de Groot PG, Meijers JC. β(2) -Glycoprotein I: evolution, structure and function. J Thromb Haemost 2011; 07: 1275-1284.
• 34 Blair TA, Moore SF, Williams CM. et al. Phosphoinositide 3-kinases p110α and p110β have differential roles in insulin-like growth factor-1-mediated Akt phosphorylation and platelet priming. Arterioscler Thromb Vasc Biol 2014; 34: 1681-1688.
• 35 Pasquet JM, Gross BS, Gratacap MP. et al. Thrombopoietin potentiates collagen receptor signalling in platelets through a phosphatidylinositol 3-kinase-dependent pathway. Blood 2000; 95: 3429-3434.
• 36 Nylander S, Kull B, Björkman JA. et al. Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost 2012; 10: 2127-2136.
• 37 Pierangeli SS, Liu SW, Anderson G. et al. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 1996; 94: 1746-1751.